| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
180,310,000 |
| Market
Cap: |
41.24(B) |
| Last
Volume: |
799,597 |
Avg
Vol: |
864,930 |
| 52
Week Range: |
$191.51 - $228.9 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Seagen is a biotechnology company that develops and commercializes targeted therapies to treat cancer. Co. is commercializing ADCETRIS®, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas, PADCEV®, or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, TIVDAK™, or tisotumab vedotin-tftv, for the treatment of certain metastatic cervical cancers, and TUKYSA®, or tucatinib, for treatment of certain metastatic HER2-positive breast cancers. Co. is also developing a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
39,326 |
484,602 |
| Total Sell Value |
$0 |
$0 |
$8,245,949 |
$88,100,996 |
| Total People Sold |
0 |
0 |
7 |
8 |
| Total Sell Transactions |
0 |
0 |
18 |
70 |
| End Date |
2024-03-28 |
2023-12-26 |
2023-06-27 |
2022-06-27 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Baker Felix |
Director |
– • • |
2011-08-25 |
4 |
B |
$15.35 |
$15,253,844 |
I/I |
984,850 |
14,646,893 |
2.25 |
- |
|
| Baker Felix |
Director |
– • • |
2011-08-25 |
4 |
B |
$15.35 |
$234,651 |
I/I |
15,150 |
321,375 |
2.25 |
- |
|
| Boerner Christopher S. |
SVP, Commercial |
• – – |
2011-08-24 |
4 |
A |
$0.00 |
$0 |
D/D |
4,500 |
6,301 |
|
- |
|
| Baker Felix |
Director |
– • • |
2011-08-24 |
4 |
B |
$14.98 |
$143,432 |
I/I |
9,576 |
13,662,043 |
2.25 |
- |
|
| Baker Felix |
Director |
– • • |
2011-08-24 |
4 |
B |
$14.98 |
$2,202 |
I/I |
147 |
306,225 |
2.17 |
- |
|
| Simpson Todd E |
Chief Financial Officer |
• – – |
2011-08-24 |
4 |
A |
$0.00 |
$0 |
D/D |
13,334 |
49,242 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2011-08-24 |
4 |
A |
$0.00 |
$0 |
D/D |
60,000 |
1,028,804 |
|
- |
|
| Seeley Bruce J. |
EVP, Commerical |
• – – |
2011-08-24 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
18,861 |
|
- |
|
| Himes Vaughn B |
EVP, Technical Operations |
• – – |
2011-08-24 |
4 |
A |
$0.00 |
$0 |
D/D |
11,334 |
17,643 |
|
- |
|
| Rosenberg Morris |
EVP, Process Sciences |
• – – |
2011-08-24 |
4 |
A |
$0.00 |
$0 |
D/D |
11,334 |
17,643 |
|
- |
|
| Reynolds Thomas C |
Chief Medical Officer |
• – – |
2011-08-24 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
30,169 |
|
- |
|
| Dobmeier Eric |
Chief Operating Officer |
• – – |
2011-08-24 |
4 |
A |
$0.00 |
$0 |
D/D |
17,334 |
59,327 |
|
- |
|
| Baker Felix |
Director |
– • • |
2011-08-23 |
4 |
B |
$14.60 |
$2,528,388 |
I/I |
171,009 |
13,652,467 |
2.25 |
- |
|
| Baker Felix |
Director |
– • • |
2011-08-23 |
4 |
B |
$14.60 |
$38,870 |
I/I |
2,629 |
306,078 |
2.25 |
- |
|
| Boerner Christopher S. |
SVP, Commercial |
• – – |
2011-08-19 |
4 |
A |
$0.00 |
$0 |
D/D |
819 |
1,801 |
|
- |
|
| Simpson Todd E |
Chief Financial Officer |
• – – |
2011-08-19 |
4 |
A |
$0.00 |
$0 |
D/D |
7,886 |
35,908 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2011-08-19 |
4 |
A |
$0.00 |
$0 |
D/D |
18,137 |
968,804 |
|
- |
|
| Seeley Bruce J. |
EVP, Commerical |
• – – |
2011-08-19 |
4 |
A |
$0.00 |
$0 |
D/D |
6,309 |
8,861 |
|
- |
|
| Himes Vaughn B |
EVP, Technical Operations |
• – – |
2011-08-19 |
4 |
A |
$0.00 |
$0 |
D/D |
6,309 |
6,309 |
|
- |
|
| Rosenberg Morris |
EVP, Process Sciences |
• – – |
2011-08-19 |
4 |
A |
$0.00 |
$0 |
D/D |
6,309 |
6,309 |
|
- |
|
| Reynolds Thomas C |
Chief Medical Officer |
• – – |
2011-08-19 |
4 |
A |
$0.00 |
$0 |
D/D |
7,886 |
10,169 |
|
- |
|
| Dobmeier Eric |
Chief Operating Officer |
• – – |
2011-08-19 |
4 |
A |
$0.00 |
$0 |
D/D |
7,886 |
41,993 |
|
- |
|
| Reynolds Thomas C |
Chief Medical Officer |
• – – |
2011-08-01 |
4 |
AS |
$17.37 |
$26,732 |
D/D |
(1,539) |
1,488 |
|
- |
|
| Dobmeier Eric |
Chief Operating Officer |
• – – |
2011-08-01 |
4 |
OE |
$5.25 |
$131,250 |
D/D |
25,000 |
33,817 |
|
- |
|
| Simpson Todd E |
Chief Financial Officer |
• – – |
2011-07-18 |
4 |
OE |
$4.45 |
$86,500 |
D/D |
18,663 |
28,022 |
|
- |
|
1805 Records found
|
|
Page 50 of 73 |
|
|
